CG
NVO

Cutler Group’s Novo Nordisk NVO Stock Holding History

Cutler Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,076
Closed -$318K – 3184
2023
Q4 		$318K Buy
+3,076
New +$304K 0.03% 560
2022
Q4 		– Sell
-200
Closed -$9K – 4950
2022
Q3 		$9K Sell
200
-964
-83% -$51.6K ﹤0.01% 3204
2022
Q2 		$64K Sell
1,164
-3,848
-77% -$214K ﹤0.01% 1769
2022
Q1 		$278K Buy
+5,012
New +$257K 0.01% 993
2017
Q4 		– Sell
-32,686
Closed -$786K – 5597
2017
Q3 		$786K Buy
+32,686
New +$739K 0.03% 437
2017
Q1 		– Sell
-3,528
Closed -$61.4K – 6949
2016
Q4 		$63K Sell
3,528
-3,600
-51% -$65.3K ﹤0.01% 2326
2016
Q3 		$148K Buy
7,128
+6,128
+613% +$152K 0.01% 1476
2016
Q2 		$26K Sell
1,000
-4,000
-80% -$110K ﹤0.01% 3074
2016
Q1 		$135K Buy
+5,000
New +$134K 0.01% 1330

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cutler Group's NVO Position: Q1 2024 in Review

Cutler Group sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 3,076 shares — an estimated $318K sold.

Cutler Group first reported a position in NVO in Q1 2016 and held it in 9 quarters. The position peaked at $786K in Q3 2017. 1,747 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

  • Cutler Group reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 3,076 Novo Nordisk shares in Q1 2024, an estimated $318K.
  • Cutler Group first reported a position in Novo Nordisk in Q1 2016 and held it in 9 quarters.
  • Cutler Group's Novo Nordisk position peaked at $786K in Q3 2017.
  • 1,747 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.